Malaria Disease Drug Pipeline Analysis
“Malaria Disease Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Malaria. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each drug profile in development phase enables the reader to identify and understand the therapeutics associated with the Malaria disease. The information for particular drug in development process is represented in the form of tables and detailed analysis including the available Pharmacodynamics and Pharmacokinetics results.
This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the drug development process. Report also helps drug development organisation to keep track record the ongoing drug profiles being developed by their key competitor in the industry.
Following parameters for each drug profile in development phase are covered in “Malaria Disease Drug Pipeline Analysis” research report:
- Drug Profile Overview
- Active Indication
- Phase of Development
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- Patent Information
- Molecular Formula
- Pharmodynamics
- Pharmacokinetics
- Brand Names
- Development Agreements
- ATC Codes
1.1 Overview
1.2 Drug Profile
2. DEVELOPMENT PHASE: PHASE-I
2.1 Overview
2.2 Drug Profile
3. DEVELOPMENT PHASE: PHASE-I/II
3.1 Overview
3.2 Drug Profile
4. DEVELOPMENT PHASE: PHASE-II
4.1 Overview
4.2 Drug Profile
5. DEVELOPMENT PHASE: PHASE-III
5.1 Overview
5.2 Drug Profile
GlaxoSmithKline (GSK) is developing a malaria vaccine based on the malarialcircumsporozoite (CS) protein. The vaccine consists of an antigenic amino acidsequence from the CS protein of Plasmodium falciparum fused with the hepatitis Bsurface antigen. It attacks the parasite before the blood stage, preventing it frommultiplying inside red blood cells. Development originated with SmithKline Beechamwhich subsequently merged with Glaxo Wellcome to form GlaxoSmithKline. Phase IIIclinical investigation of the malaria vaccine is underway in infants in several Africancountries. In addition, a phase II trial in adults is in progress in the US.
GSK has entered into a collaboration with Crucell for the development of a secondgeneration malaria vaccine [see separate profile: Malaria vaccine-Crucell/GlaxoSmithKline]; the collaboration will focus on the development of a vaccinewhich incorporates GSK's vaccine candidate RTS, S/AS and Crucell's vaccine candidateAd35-CS.
GlaxoSmithKline and Antigenics (later Agenus) established a licensing agreement inJuly 2006 that allowed GlaxoSmithKline to use Antigenics' QS-21 (Stimulon®) adjuvantin the development of its RTS,S vaccine. GlaxoSmithKline was to make milestonepayments to Antigenics and pay royalties on net sales for a period of 10 years afterfirst commercialisation of the product. The agreement was amended in March 2012,giving GSK further rights to the adjuvant. GlaxoSmithKline paid Agenus a nonrefundablefee of $US9 million. Antigenics was renamed as Agenus in January 2011.
In 2001, a collaboration was set up between GlaxoSmithKline and the Malaria VaccineInitiative (MVI) to advance the development of RTS,S/AS02A for children in thedeveloping world. MVI's mission is to accelerate the development of malaria vaccines,and will be providing financial support and a collaborative management style to enablethe RTS,S programme to progress at a meaningful pace.
In 1991, SmithKline Beecham (later GlaxoSmithKline) licensed MPL® from RibiImmunoChem, which was integrated into Corixa in October 1999. Under the terms ofthe agreement, SmithKline Beecham was granted worldwide exclusive rights to useMPL® adjuvant in vaccines in a number of infectious disease fields. GlaxoSmithKlinewill pay Corixa transfer payments for supplies of MPL® and, royalties when productsdeveloped under the agreement are commercialised. Subsequently, Corixa wasacquired by, and merged into GlaxoSmithKline in July 2005.
